Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are the most common causes of nephrotic syndrome in children and in young adults. Relapsing MCD carries the risk of severe complications and prolonged immunosuppression, whereas FSGS remains largely untreatable and urgently needs more effective treatments. Recently, induction of B7-1 (CD80), an immune-related protein expressed by antigen-presenting cells, was observed in podocytes of MCD and FSGS patients, suggesting that B7-1 plays a role in the pathogenesis of these diseases, and hence that abatacept, a B7-1 inhibitor, could be a possible treatment. Since previous studies raised serious concerns regarding the reliability of immunohistochemical assays for B7-1 detection and the efficacy of B7-1 inhibitory treatment, we investigated B7-1 podocyte expression in MCD and FSGS patients. Using different primary antibodies and immunohistochemical assays, no significant upregulation of podocyte B7-1 was detected in patients' biopsies compared with controls. To further confirm our findings, we analyzed mice with adriamycin-induced nephropathy, a model of human FSGS, and mice injected with LPS as additional control. Podocyte B7-1 was not observed in mice injected with adriamycin or LPS either. In conclusion, since B7-1 is not induced in podocyte of MCD and FSGS patients, the antiproteinuric action of abatacept, if confirmed, may not be the result of an effect on podocyte B7-1. minimal change disease; focal segmental glomerulosclerosis; podocytes; B7-1
MINIMAL CHANGE DISEASE (MCD) is the most common cause of nephrotic syndrome in children, accounting for ϳ80 -90% of nephrotic cases in young patients (15) , while in adults it is uncommon, representing only 10 -15% of primary nephrotic syndrome cases, which are more often associated with focal segmental glomerulosclerosis (FSGS) (8) .
MCD is characterized by selective proteinuria and hypoalbuminemia (14) , and its only recognizable histological alterations concern podocytes, with extensive foot process effacement and downregulation/disorganization of podocyte-and slit-pore membrane-associated proteins (12) . The prognosis of MCD patients is typically favorable, especially in children, in whom current standard therapy, consisting of oral steroids, is generally effective in inducing complete remission within weeks (23) . However, more than 50% of patients may relapse (12) , with an increased risk of prolonged immunosuppression due to repeated courses of steroids and other agents to control the effects of nephrotic syndrome (16) . In FSGS, the most prominent feature is progressive glomerular scarring, initially focal, involving a minority of glomeruli, and segmental, partially affecting the glomerular tuft, and then it becomes more extensive and global as the disease progresses (5) . FSGS, both primary and recurrent after transplantation, is still largely untreatable, and patients are at substantial risk of progressing to end-stage renal disease (5) . Thus, relapsing MCD, as well as resistant FSGS patients, who are at increased risk of severe complications, urgently need new, safer, and more effective treatments.
The recent observation of B7-1 induction in podocytes of these patients offered an exciting unexpected hope to find a treatment for these intractable diseases. B7-1 (CD80) is a costimulatory ligand expressed on the surface of antigenpresenting cells (APCs), whose binding to the T-cell receptors CD28 and CTLA-4 is essential for activating and regulating T-cell immunity (3) . In the last few years, B7-1 induction was observed in podocytes of proteinuric patients with lupus nephritis (22) , membranous nephropathy (25) , and diabetic nephropathy (7) . Moreover, recent studies hypothesized a role for podocyte B7-1/CD80 in MCD (4, 10, 11) and FSGS (25) diseases. Garin et al. (10, 11) observed high levels of B7-1 in urine samples from subjects with relapsing MCD, associated with intense podocyte B7-1 expression in patients' biopsies. Glomerular B7-1 expression was also described in subjects with FSGS, both primary and recurrent (25) . As a result, B7-1 expression in podocytes was proposed as a biomarker for defining disease and guiding treatment of various glomerulopathies. Thus the use of costimulatory inhibitors targeting B7-1, abatacept and belatacept, which are currently used for treating rheumatoid arthritis and acute kidney rejection, was suggested as promising therapy at least in a subset of patients with highly expressed podocyte B7-1 (20) . However, previous attempts at evaluating podocyte B7-1 expression and the therapeutic effect of its blockade in proteinuric patients were disappointing, and several groups expressed doubts about the reliability of immunohistochemical assays used to detect B7-1 in renal specimens (2, 9, 17, 18) , as well as the effectiveness of B7-1 inhibitory treatment (1, 11, 13) . Using different immunohistochemical techniques, podocyte B7-1 staining was not detected in kidney biopsies of large cohorts of patients affected by various renal diseases; instead, nonspecific staining due to the reactivity of the secondary antibody with the deposited IgG was repeatedly described (2, 9, 17, 18) . As regards the clinical response, after the excitement about proteinuria remission induced by abatacept in five FSGS patients (25), Alachkar et al. (1) described five cases of patients with posttransplant recurrent FSGS who did not experience remission after abatacept treatment, despite B7-1-positive podocytes in their kidney biopsies. Subsequently, Garin et al. (11) described only transient resolution of proteinuria in one MCD patient, and unchanged proteinuria levels in one patient with primary FSGS and in two of three patients with recurrent FSGS after B7-1 blockade therapy, despite the presence of B7-1 glomerular staining. Finally, Grellier et al. (13) did not detect B7-1 staining in the glomeruli of five patients with recurrent FSGS in whom belatacept treatment was unsuccessful.
Given the crucial importance of this highly controversial topic and the tireless interest of the scientific community in searching for breakthroughs for the treatment of devastating kidney diseases, here we investigated whether B7-1 was truly expressed in podocytes of our MCD and FSGS patient cohorts.
MATERIALS AND METHODS
Patient enrollment. Renal tissues were obtained from biopsy specimens from 15 patients affected by MCD and 16 patients with FSGS who were admitted for diagnostic reasons to the Nephrology Unit of the Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy. Demographic, clinical, and histological parameters at the time of the renal biopsy were retrieved from the hospital database. Renal biopsy specimens from the uninvolved portion of the kidney, collected for tumor nephrectomy from four age-and sex-matched nonproteinuric patients, were used as normal controls. Written, informed consent to undergo renal biopsy evaluations was obtained from all the patients enrolled in the study.
Experimental models. Male Balb/c mice (Charles River Laboratories Italia, Calco, Italy) were injected in the tail-vein with a single dose of adriamycin (ADR) (10.5 mg/kg; Pfizer Italia, Latina, Italy), as described. ADR-injected mice (n ϭ 4) were euthanized 4 wk after disease induction. Healthy mice euthanized at 4 wk (n ϭ 4) served as controls. Proteinuria was determined by the Coomassie method using a Cobas Mira auto-analyzer (Roche Diagnostic Systems, Basel, Switzerland). Male C57BL/6 mice were obtained from Charles River Laboratories Italia (Lecco, Italy). Lipopolysaccharide (LPS; 400 g/ mouse; O111:B4; Sigma-Aldrich, St. Louis, MO) was intraperitoneally injected in mice (26 -28 g body wt), which were euthanized 24 h after injection (n ϭ 3). Mice injected with saline served as controls (n ϭ 3). Renal function was measured by serum blood urea nitrogen (Reflotron test; Roche Diagnostics, Basel, Switzerland). Animal care and treatment were in accordance with institutional guidelines, in compliance with national (Decreto Legislativo n.116, Gazzetta Ufficiale suppl 40, 18 febbraio 1992, Circolare n. housed in a constant-temperature room with a 12:12-h dark-light cycle and fed a standard diet.
Immunofluorescence and immunoperoxidase analysis on renal tissue. Snap-frozen renal specimens of MCD and FSGS patients and mice were used for immunofluorescence analysis. Snap-frozen kidney biopsies were cut in 3-m sections and air-dried for 10 min at room temperature. Sections were fixed in cold acetone for 10 min and then washed in PBS twice for 5 min. After nonspecific sites were blocked with 1% bovine serum albumin (BSA), slides were incubated with polyclonal goat anti-human B7-1 (diluted 1:200; R&D Systems, McKinley Place, Minneapolis, MN; catalog number AF140), or polyclonal goat anti-mouse B7-1 (1:100; R&D Systems; catalog number AF740), or monoclonal hamster anti-mouse B7-1 (1:20; clone 16-10A1, BD Pharmingen, San Diego, CA; catalog number 553766), and mouse anti-human podocalyxin (PDX; 1:150, gift from Prof. Robert Atkins, Department of Nephrology, Monash Medical Centre, Clayton, VIC, Australia), or rabbit anti-mouse PDX (1:100, Novus Bio, Southpark Way, Littleton, CO), or mouse anti-human CD20 (1:100, Dako, Glostrup, Denmark), or hamster anti-mouse CD11c (1:20, BD Pharmingen), followed by the specific Cy3-and FITC-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA), previously exposed to either BSA or strain-specific murine serum. On human biopsies, we used a human IgG-adsorbed secondary antibody. Nuclei were stained with 4=,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, Milan, Italy), and the renal structure with lectin fluorescein wheat germ agglutinin (Vector Laboratories, Burlingame, CA). Negative controls were obtained by omitting the primary antibody on adjacent serial sections. Fluorescence was examined using an inverted confocal laser scanning microscope (LS 510 Meta, Carl Zeiss, Jena, Germany). Quantification of the B7-1-positive glomerular area was performed in all glomeruli found in human biopsies and expressed as a percentage of positive area on total glomerular tuft area. For B7-1 immunoperoxidase staining, DuboscqBrazil-fixed paraffin-embedded human kidney sections were deparaffinized and rehydrated. Antigen retrieval was performed by boiling sections in a decloaking chamber (DC NxGen 220V, Biocare Medical) for 15 min at 110°C with DIVA decloaker buffer (Biocare Medical), then sections were incubated for 5 min with peroxidazed 1 (Biocare Medical, Concorde, CA) to quench endogenous peroxidase. After blocking for 5 min with background punisher (Biocare Medical), sections were incubated with monoclonal mouse anti-human B7-1 (1:50; clone 37711, R&D Systems, catalog number MAB140), followed by MACH4 HRP-polymer kit (Biocare Medical) and diaminobenzidine (Biocare Medical) substrate solution.
Immunofluorescence analysis of LPS-activated human splenocytes. Human splenocytes (routinely collected from kidney donors at our Transplant Research Centre for immunological studies) were cultured for 72 h in RPMI-1640 medium (Invitrogen, Gaithersburg, MA), supplemented with 20% male antibody human serum (resting condition) or with 50 g/ml LPS (from E. coli D26:B6, Sigma Aldrich), as previously described (9) . After incubation, cells were washed, cytocentrifuged on glass slides, and then fixed in 2% paraformaldehyde and 4% sucrose for 5 min. After blockade of nonspecific binding sites with 1% BSA, cells were incubated over night with goat anti-human B7-1 antibody (1:50, R&D Systems AF140), followed by rabbit anti-goat Cy3-conjugated secondary antibody (Jackson ImmunoResearch Laboratories). Nuclei were stained with DAPI (Sigma-Aldrich), and negative controls were obtained by omitting primary antibody. Fluorescence was examined by an inverted confocal laser scanning microscope (LS 510 Meta, Carl Zeiss).
Statistical analysis. Results are expressed as mean values Ϯ SE. Data were analyzed using t-test for unpaired data. P Ͻ 0.05 was considered a statistically significant difference.
RESULTS AND DISCUSSION
We analyzed B7-1 protein expression in the kidney biopsies of 15 patients with diagnosed MCD and 16 with FSGS. Four uninvolved portions of kidneys collected from tumor nephrectomy samples served as controls. Clinical features of the analyzed patients are displayed in Table 1 . In our cohort, 11 patients with MCD and 13 with FSGS had primary renal disease, while 4 MCD patients and 3 with FSGS had a secondary recognized cause of nephrotic syndrome, in most cases represented by chronic infections or hematological diseases.
Four subjects with MCD and two with FSGS experienced pediatric disease onset. Among MCD patients, five were in steroid-induced complete remission (urine proteins Ͻ0.3 g/day) at the time of the biopsy, while the remaining 10 patients had nephrotic syndrome, despite two of them apparently having nonnephrotic proteinuria levels (patient 10, 1.25 g/day, and patient 13, 2.7 g/day). Conversely, all FGSG patients were proteinuric at the time of biopsy: 14 patients had severe nephrotic syndrome, and only 2 had nonnephrotic proteinuria. As regards steroid sensitivity, all 11 primary MCD patients received steroids and had achieved remission; of these, 8 became steroid dependent over follow-up. FSGS patients were more clinically heterogeneous: 7 of the 13 patients who had received steroids were steroid resistant, and 4 of the 6 steroid-sensitive patients developed steroid dependency. Snapfrozen bioptic renal specimens of subjects belonging to our patient cohort were stained using polyclonal goat anti-human B7-1 through indirect immunofluorescence, as previously described (2, 9). B7-1 was completely absent in glomeruli of all control subjects (Fig. 1A) . In three MCD patients, no glomerular B7-1 expression was found (Fig. 1B) , while few traces of B7-1 were observed in the glomeruli of the remaining subjects (Fig. 1D, inset) . The quantification of B7-1 staining in MCD patients' glomeruli revealed that only an average of 0.54 Ϯ 0.12% (mean value Ϯ SE) of the glomerular area was positive for B7-1 (Table 1 ). No differences in glomerular B7-1 expression were observed between patients in remission and those relapsing, or between those with pediatric or adult onset of the Fig. 1 . Glomerular B7-1 is not induced in minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) patients. A-H: representative micrographs of B7-1 indirect immunofluorescence staining using the polyclonal goat anti-B7-1 antibody (pAb; red) in frozen kidney biopsies of control subjects, MCD and FSGS patients, and in lipopolysaccharide (LPS)-treated human splenocytes. Nuclei were stained with 4=,6-diamidino-2-phenylindole (DAPI; blue). A: B7-1 was not detectable in control glomeruli. B: in 3 MCD patients from our cohort, no B7-1 staining was detectable in glomeruli, although it was expressed by infiltrating inflammatory cells (arrowheads). C: FSGS patients did not displayed a significant glomerular B7-1 staining, even though strong B7-1 positivity was detected on interstitial cells (arrowheads). Renal structures were stained with fluorescein wheat germ agglutinin (WGA; green). D and E: co-staining with podocalyxin (PDX; green), a podocyte-specific marker, documented that podocytes did not express B7-1 in either MCD (D) or FSGS patients (E). F: B7-1 was abundantly expressed by LPS-activated human splenocytes. G and H: the few interstitial B7-1 positive inflammatory cells also express the B cell marker CD20 (green) (insets and arrowheads). I-K: representative images of B7-1 immunoperoxidase staining using the monoclonal mouse anti-B7-1 antibody (mAb) in paraffin-embedded renal biopsies of control subjects and MCD and FSGS patients. I: B7-1 was absent in controls' renal biopsies. Glomeruli of MCD (J) and FSGS (K) patients were negative for B7-1, whereas interstitial inflammatory cells and injured epithelial tubular cells displayed strong B7-1 positivity. Bar: 50 m.
disease. The same observations were made in FSGS patients' biopsies. Two subjects were completely negative for glomerular B7-1, while in the remaining patients granular traces of B7-1 staining were occasionally detected along the periphery of the glomerular capillary loops (Fig. 1C) . The quantification of B7-1 staining in all glomeruli found in FSGS biopsies revealed that it occupied a mean of 0.73 Ϯ 0.11% of the tuft area, with a maximum of 1.49 Ϯ 0.49% observed in one patient (Table 1 ). Primary and secondary FSGS patients displayed comparable glomerular B7-1 staining independent of steroid sensitivity. Glomerular staining that we quantified in frozen samples from both MCD and FSGS patients was often the result of an automatic subtraction (made using ImageJ software) of the signal obtained on the consecutive section treated with the secondary antibody alone (negative control), and, in any case, it was so weak as to appear nonspecific. The costaining with PDX, a podocyte-specific marker, further confirmed that podocytes did not express B7-1 in either MCD or FSGS patients (Fig. 1, D and E) . The reliability of the primary antibody used for human B7-1 detection was verified analyzing human splenocytes that, when exposed to LPS, are a good source of B7-1, as previously described (21) . The positive staining we observed in LPS-activated human splenocytes unequivocally demonstrated that the primary antibody was indeed specific for human B7-1 (Fig. 1F) . Moreover, B7-1-positive interstitial inflammatory cells (Fig. 1, B, C, G , and H, arrowheads and insets) and injured epithelial tubular cells (Fig.  1, B and G) that could acquire antigen-presenting function (24) found in patients' biopsies attested that the B7-1 epitope was not degraded in the analyzed samples. As expected, double immunostaining revealed that B7-1-positive infiltrating inflammatory cells also expressed the B cell marker CD20 (Fig. 1, G and H, arrowheads and insets) (6) . These findings further confirmed the specificity of the employed antibodies and the reliability of our immunostaining assays for B7-1 detection when and where it is truly expressed.
To confirm these observations, another assay for B7-1 detection was performed. Duboscq-fixed and paraffin-embedded renal bioptic samples of all MCD and FSGS patients were stained with a monoclonal mouse anti-human B7-1 antibody using a previously described immunoperoxidase protocol with antigen retrieval (9, 17) . B7-1 was not expressed in glomeruli of all analyzed patients (Fig. 1, J and K) , even though clearly detectable interstitial inflammatory cells and tubular epithelial cells were strongly B7-1 positive (Fig. 1, J and K) , providing internal positive controls for the reliability of the B7-1 detection assay on paraffin-embedded sections.
Moving from patients to the experimental model, we analyzed B7-1 expression in kidneys from Balb/c mice injected with ADR, a model that faithfully resembles human FSGS histological lesions (19) . Balb/c mice not injected with ADR served as controls. Snap-frozen murine kidney specimens were stained through indirect immunofluorescence using two different anti-mouse B7-1 antibodies, one polyclonal and one monoclonal, followed by secondary antibodies formerly exposed to the strain-specific murine serum, as previously described (9) . At 4 wk after disease induction, overt nephropathy and proteinuria occurred (36.43 Ϯ 5.83 mg/day vs. controls: 1.47 Ϯ 0.28 mg/day, P value Ͻ 0.01). Glomerular B7-1 expression was not detectable in the ADR-injected Balb/c renal specimens, either with the polyclonal (Fig. 2B ) or monoclonal antibody (Fig. 2C) , similar to controls (Fig. 2A) . Co-immunostaining using the podocyte-specific marker PDX further documented that podocytes of ADR-injected mice did not express B7-1 (Fig. 2D) . By contrast, strong B7-1 positivity was observed in interstitial inflammatory cells (Fig. 2, C and E, arrowheads) that also expressed the dendritic cell marker CD11c (Fig. 2E, arrowheads) , revealing that B7-1-positive interstitial cells were APCs. The presence of internal positive controls ensures the reliability of our antibodies and experimental protocols. Since B7-1 expression in murine podocytes was first described in LPS-injected mice (22) , we also analyzed frozen kidney specimens from C57BL/6 mice with renal insufficiency induced by injection of LPS (blood urea nitrogen: 111.23 Ϯ 1.87 mg/dl vs. controls: 17.53 Ϯ 2.2 mg/dl, P value Ͻ 0.0001). In these additional controls, double staining with PDX showed that B7-1 was not upregulated in podocytes of LPS mice (Fig. 2G ), in contrast with previous findings (22) . B7-1 expression was confined on interstitial inflammatory cells, which were CD11c-positive APCs (Fig. 2, G and H) .
Although the concept of biomarker-driven customized nephrology using B7-1 podocyte expression as a discriminatory feature for treatment with abatacept or belatacept gave new hope, the present data cast further doubt on its reliability. Although we analyzed a considerable number of patients with heterogeneous clinical features, no significant upregulation of podocyte B7-1 emerged, and no glomerular B7-1 was found in ADR and LPS-injected mice. Moreover, this study, with a double investigation of podocyte B7-1 expression in both frozen and paraffin-embedded patients' biopsies, and irrefutable internal positive controls, helps us to understand that paraffin-embedded samples are as reliable as frozen ones when used for detecting B7-1.
Is it possible to generate a data-driven consensus on podocyte B7-1 expression and its therapeutic targeting in renal diseases? A fair answer to this question is threefold: 1) expression of B7-1 in podocytes of patients with MCD and FSGS is not detectable by immunostaining of frozen or fixed kidney biopsy tissue, nor in kidney tissues of an animal model mimicking the human condition. Albeit highly unlikely, we cannot exclude the possibility that B7-1 expression by podocytes is present, but at levels that are too low for detection by immunostaining techniques. By contrast, in these very same biopsies, B7-1 is clearly detectable in infiltrating inflammatory cells, offering a strong argument for the robustness of negative results; 2) B7-1 cannot be considered a biomarker of disease activity and progression in the above-mentioned clinical conditions; 3) the antiproteinuric action of abatacept in MCD and FSGS is disputed. If confirmed in rigorously designed studies, it may be the consequence of inhibiting immune cell activation rather than an action on podocytes.
With this in mind, we should not hasten to use B7-1 blockers to treat MCD and FSGS patients before results from all the ongoing studies on podocyte B7-1 expression are available. Until that moment, even the rationale for embarking on clinical trials with abatacept or belatacept is questionable.
